Cortactin overexpression results in sustained epidermal growth factor receptor signaling by preventing ligand-induced receptor degradation in human carcinoma cells by van Rossum, Agnes GSH et al.
235 EGFR = epidermal growth factor receptor.
Available online http://breast-cancer-research.com/content/7/6/235
Abstract
The chromosome 11q13 region is frequently amplified in human
carcinomas and results in an increased expression of various
genes including cortactin, and is also associated with an increased
invasive potential. Cortactin acts as an important regulator of the
actin cytoskeleton. It is therefore very tempting to speculate that
cortactin is the crucial gene within the 11q13 amplicon that
mediates the invasive potential of these carcinomas. Cortactin also
participates in receptor-mediated endocytosis, and recent findings
have shown that, during receptor internalization, cortactin
overexpression inhibits the ubiquitylation-mediated degradation of
the epidermal growth factor receptor, resulting in a sustained
ligand-induced epidermal growth factor receptor activity.
Cell structure is maintained by the combined action of
microtubules, intermediate filaments and the actin cyto-
skeleton. Actin filaments contribute to alterations in the cell
shape, motility, adhesion, polarization, contraction, cyto-
kinesis, signal transduction, endocytosis and intracellular
vesicle trafficking. Cortactin [1], as a regulator of actin cyto-
skeleton organization, is involved in many of these processes
(reviewed in [2,3]). For instance, many observations revealed
that cells overexpressing cortactin show enhanced cell
migration, invasion and increased metastatic potential in vivo
[4-6]. Furthermore, downregulation of cortactin in highly
invasive cells in vitro using small RNA interference (van
Rossum, Moolenaar, Schuuring, unpublished research),
deletion mutants or microinjection of antibodies resulted in a
decreased invasive potential [4,6,7].
Interestingly, human cortactin was identified as one of the
overexpressed genes within the amplified chromosome
11q13 region [8,9]. The 11q13 region is frequently amplified
in human malignancies such as breast carcinomas (13%) and
head/neck carcinomas (36%) [10,11]. In these patients, both
11q13 amplification and cortactin overexpression correlate
with markers indicative of poor prognosis, such as the
presence of lymph node metastases [10-12]. Because
cortactin acts as a regulator of the actin cytoskeleton
integrity, it is tempting to speculate that cortactin mediates
the invasive and metastatic potential of carcinomas with
11q13 amplification.
With the identification of the growing number of cortactin-
interacting proteins, novel functions of cortactin have
emerged [2,13]. Cortactin has been implicated in endo-
cytosis by its localization in endosomal vesicles [14]. Further-
more, GTPase dynamin-2 was identified as a cortactin-
interacting protein and, as such, linked the actin cytoskeleton
to clathrin-dependent endocytosis [15]. More recent studies
[16-18] provide convincing evidence that cortactin is involved
in dynamin-mediated, clathrin-dependent endocytosis. Many
growth factor receptors, including epidermal growth factor
receptor (EGFR), are regulated via this classic endocytic
pathway (reviewed in [19,20]). The ligand-induced EGFR is
trapped on the plasma membrane into clathrin-coated pits,
which is followed by the formation of clathrin-coated vesicles
by dynamin-mediated fission and fusion. These vesicles form
early endosomes that can mature towards late lysosomal
endosomes. Under certain circumstances, however, the
EGFR might be prevented from entering the lysosomal
endosome and may become recycled to the cell surface, a
mechanism that fine-tunes the activity of the EGFR [19].
It was recently demonstrated that ubiquitylation by Cbl
triggers the EGFR to enter lysosomal endosomes, resulting in
its degradation (reviewed by [20]). For instance, the EGFR
with mutations at the Cbl-docking site will not be degraded
and is recycled back to the plasma membrane. Other
members of the ErbB-family, such as ErbB2, that lack a
docking site for Cbl, can form heterodimers with the EGFR.
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This thereby reduces the ability of the EGFR to associate
with Cbl, resulting in an increased recycling of the receptor.
Finally, EGFRvIII, a mutant found in glioblastoma that lacks a
portion of the extracellular domain, showed defects in
internalization and ubiquitylation by Cbl.
Timpson and colleagues hypothesized in an earlier issue of
Cancer Research that cortactin is also involved in modulating
EGFR activity [21]. They showed that the EGFR is degraded
less efficiently in cells with increased cortactin expression, and
that the EGFR activity upon ligand stimulation is sustained. In
agreement with these experiments, expression of cortactin
correlated well with ligand-stimulated EGFR signal trans-
duction in cell lines derived from head/neck carcinomas. In
addition, increased expression levels of cortactin did not
significantly influence EGFR internalization, but resulted in
accelerated recycling — leading the authors to speculate that
cortactin might have an effect on the transfer of the EGFR from
the early to the late lysosomal endosomes. Indeed, the EGFR
was not efficiently ubiquitylated in cells that overexpressed
cortactin, resulting in inhibition of the ligand-induced down-
regulation of the receptor and sustained epidermal growth
factor-induced Erk activity. The decrease in ubiquitylation was
accompanied by the inhibition of Cbl binding to the EGFR.
The mechanism for the observed effects of cortactin over-
expression on Cbl function is presently unclear. The authors
discuss several possibilities to explain the impaired Cbl
activity [21]. Activated Cdc42 binds to Cbl via p85Cool-1/β-Pix
and prevents Cbl interacting with the EGFR, thus preventing
receptor ubiquitylation [22]. Fgd1, a Cdc42 guanine nucleo-
tide exchange factor, was recently identified to interact with
cortactin [23]. Overexpression of cortactin might therefore
activate Cdc42 via Fgd1, leading to Cdc42/p85Cool-1/β-
Pix/Cbl complex formation and consequently reducing the
interaction of Cbl to the EGFR. Timpson and colleagues [21]
demonstrated that Cbl tyrosine phosphorylation as well its
interaction with the EGFR was reduced in cortactin-
overexpressing cells, whereas the amount of Cbl was not
affected. Cbl is a substrate for nonreceptor tyrosine kinase
Src, and phosphorylation of Cbl is necessary to activate its
ubiquitin ligase activity [24]. Overexpression of cortactin, one
of the most prominent substrates for Src, might therefore
sequester Src from Cbl to prevent Cbl phosphorylation and
thereby prevent its ability to ubiquitylate the EGFR. Finally,
cortactin overexpression did not cause EGFR internalization,
but after 60–120 min of epidermal growth factor stimulation
the EGFR reappeared on the cell surface. At the same time,
degradation of the EGFR was also observed in cortactin-
overexpressing cells. Since no degradation of the EGFR was
observed until 30 min of epidermal growth factor stimulation
in these cells, the enhancement of Erk activation after
5–10 min of epidermal growth factor stimulation suggests an
altered trafficking between specific endosomal compartments
[21]. However, it is not known exactly how cortactin affects
EGFR trafficking.
In conclusion, it is presently unclear how cortactin over-
expression impairs Cbl phosphorylation and consequent
ubiquitylation of the EGFR. Recent reports provide
convincing evidence that cortactin is an important regulator
during receptor-mediated endocytosis by its interaction with
dynamin and actin [16-18]. However, the work by Timpson
and colleagues [21] demonstrated that cortactin can interfere
directly or indirectly with ligand-induced downregulation of
the EGFR. These authors showed that increased expression
of cortactin resulted in the inhibition of EGFR degradation
and sustained EGFR activity. Together with the observation
that the EGFR has already been reported to be activated in
carcinomas of the head/neck region due to EGFR DNA
amplification [25], these observations imply that constitutive
EGFR activity is present in a significant number of these
carcinomas. It would be of interest to learn about the role of
cortactin expression in regulating the endocytosis of other
receptors and cell adhesion molecules.
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